Preclinical cardiac safety assessment of pharmaceutical compounds using an integrated systems-based computer model of the heart

被引:44
作者
Bottino, D
Penland, RC
Stamps, A
Traebert, M
Dumotier, D
Georgieva, A
Helmlinger, G
Lett, GS
机构
[1] Univ S Carolina, Dept Chem Engn, Columbia, SC 29208 USA
[2] Novartis Pharma AG, Safety Profiling & Assessment, Basel, Switzerland
[3] Novartis Pharmaceut, Modeling & Simulat, E Hanover, NJ USA
关键词
D O I
10.1016/j.pbiomolbio.2005.06.006
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Blockade of the delayed rectifier potassium channel current, I-Kr, has been associated with drug-induced QT prolongation in the electrocardiogram and life-threatening cardiac arrhythmias. However, it is increasingly clear that compound-induced interactions with multiple cardiac ion channels may significantly affect QT prolongation that would result from inhibition of only I-Kr [Redfern, W.S., Carlsson, L., et al., 2003. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc. Res. 58(1), 32-45]. Such an assessment may not be feasible in vitro, due to multifactorial processes that are also time-dependent and highly non-linear. Limited preclinical data, I-Kr hERG assay and canine Purkinje fiber (PF) action potentials (APs) [Gintant, G.A., Limberis, J.T., McDermott, J.S., Wegner, C.D., Cox, B.F., 2001. The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis. J. Cardiovasc. Pharmacol. 37(5), 607-618], were used for two test compounds in a systems-based modeling platform of cardiac electrophysiology [Muzikant, A.L., Penland, R.C., 2002. Models for profiling the potential QT prolongation risk of drugs. Curr. Opin. Drug. Discov. Dev. 5(1), 127-35] to: (i) convert a canine myocyte model to a PF model by training functional current parameters to the AP data; (ii) reverse engineer the compounds' effects on five channel currents other than I-Kr, predicting significant IC50 values for I-Na+,I-sustained and ICa2+ which were subsequently experimentally validated; (111) use the predicted,L-type, (I-Na+,I-sustained and I-Ca2+,I-L-type) and measured (I-Kr) IC50 values to simulate dose-dependent effects of the compounds on APs in endocardial, mid-myocardial, and epicardiac ventricular cells; and (iv) integrate the three types of cellular responses into a tissue-level spatial model, which quantifiably predicted no potential for the test compounds to induce either QT prolongation or increased transmural dispersion of repolarization in a dose-dependent and reverse rate-dependent fashion, despite their inhibition of I-Kr in vitro. (c) 2005 Published by Elsevier Ltd.
引用
收藏
页码:414 / 443
页数:30
相关论文
共 90 条
[21]   Ionic mechanisms responsible for the electrocardiographic phenotype of the Brugada syndrome are temperature dependent [J].
Dumaine, R ;
Towbin, JA ;
Brugada, P ;
Vatta, M ;
Nesterenko, DV ;
Nesterenko, VV ;
Brugada, J ;
Brugada, R ;
Antzelevitch, C .
CIRCULATION RESEARCH, 1999, 85 (09) :803-809
[22]   Multiple mechanisms of Na+ channel-linked long-QT syndrome [J].
Dumaine, R ;
Wang, Q ;
Keating, MT ;
Hartmann, HA ;
Schwartz, PJ ;
Brown, AM ;
Kirsch, GE .
CIRCULATION RESEARCH, 1996, 78 (05) :916-924
[23]  
Dumotier BM, 1999, DRUG DEVELOP RES, V47, P63, DOI 10.1002/(SICI)1098-2299(199906)47:2<63::AID-DDR2>3.3.CO
[24]  
2-X
[25]  
ElSherif N, 1997, CIRCULATION, V96, P4392
[26]  
*FDA, 2004, CLIN EV QT QTC INT P
[27]  
*FDA, 2003, M AN LIF SUPP DRUGS
[28]   Generating and influencing Torsades de Pointes-like polymorphic ventricular tachycardia in isolated guinea pig hearts [J].
Gerhardy, A ;
Scholtysik, G ;
Schaad, A ;
Haltiner, R ;
Hess, T .
BASIC RESEARCH IN CARDIOLOGY, 1998, 93 (04) :285-294
[29]   The canine Purkinje fiber: An in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis [J].
Gintant, GA ;
Limberis, JT ;
McDermott, JS ;
Wegner, CD ;
Cox, BF .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2001, 37 (05) :607-618
[30]   Methods of collecting and evaluating non-clinical cardiac electrophysiology data in the pharmaceutical industry: results of an international survey [J].
Hammond, TG ;
Carlsson, L ;
Davis, AS ;
Lynch, WG ;
MacKenzie, I ;
Redfern, WS ;
Sullivan, AT ;
Camm, AJ .
CARDIOVASCULAR RESEARCH, 2001, 49 (04) :741-750